Honorable Myra Crownover, Chair, House Committee on Public Health
FROM:
Ursula Parks, Director, Legislative Budget Board
IN RE:
HB2675 by Larson (Relating to exempting manufacturers engaged in certain commercial research and development from registration under the Texas Controlled Substances Act.), As Introduced
No significant fiscal implication to the State is anticipated.
The bill would amend the Health and Safety Code to exempt manufacturers engaged in certain commercial research and development from registration under the Texas Controlled Substances Act. It is assumed any costs associated with implementing the provisions of the bill could be absorbed within existing resources and that any revenue loss associated with the fee exemption would not be significant.
Local Government Impact
No significant fiscal implication to units of local government is anticipated.